Top of page
Lawyers

Jonathan Cooklin

Lawyers

Filters

Royalty Pharma $6 billion senior notes offering

Davis Polk advised Royalty Pharma plc in connection with its Rule 144A/Regulation S offering of $1 billion aggregate principal amount of its 0.75% senior notes due 2023, $1 billion…

Freeline Therapeutics Holdings $158.8 million IPO

Davis Polk advised Freeline Therapeutics Holdings plc on its $158.8 million initial public offering of 8,823,529 American depositary shares representing 8,823,529 ordinary shares, which…

Unification of Unilever’s corporate structure

Davis Polk is advising UBS AG London Branch as sponsor in connection with the unification of Unilever’s dual-headed group legal structure under a single parent company, Unilever PLC, to be…

Royalty Pharma $2.5 billion IPO

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering of 89,333,920 of its Class A ordinary shares, which included an…

Clarivate $1.08 billion ordinary shares offering

Davis Polk advised Clarivate Plc in connection with the $1.08 billion SEC-registered offering of 48,000,000 of its ordinary shares, of which 14,000,000 ordinary shares were issued and sold…
Back to top